http://www.presseportal.de/pm/14390/pfizer-inc/rssPresseportal.de: Pfizer Inc. (Digitale Pressemappe)de-denews aktuell GmbHhttp://www.presseportal.de/images/logo_napresseportal.gifhttp://www.presseportal.de/pm/14390/pfizer-inc/rssredaktion@presseportal.de (Jens Petersen)Sat, 11 Feb 2012 02:38:53 +0100Tue, 06 Jul 2010 09:06:15 +02006Pfizer Inc.: New York, July 6, 2010 (ots/PRNewswire) - Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") ...http://www.presseportal.de/pm/14390/1643213/pfizer-announces-european-union-approval-of-a-new-form-of-lipitor-atorvastatin-for-use-in-children/rssTue, 06 Jul 2010 09:06:15 +0200http://www.presseportal.de/pm/14390/1643213/pfizer-announces-european-union-approval-of-a-new-form-of-lipitor-atorvastatin-for-use-in-children/rss Pfizer Inc. [Pressemappe]
New York, July 6, 2010 (ots/PRNewswire) - Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: Rome, June 8, 2010 (ots/PRNewswire) - UK Premiership footballer Rory Delap, renowned for his devastating throw-in, has joined forces with a number of football heroes across Europe to support 'Back in Play', a European wide campaign to reach young ...http://www.presseportal.de/pm/14390/1627168/football-stars-unite-to-tackle-back-pain/rssTue, 08 Jun 2010 07:01:25 +0200http://www.presseportal.de/pm/14390/1627168/football-stars-unite-to-tackle-back-pain/rss Pfizer Inc. [Pressemappe]
Rome, June 8, 2010 (ots/PRNewswire) - UK Premiership footballer Rory Delap, renowned for his devastating throw-in, has joined forces with a number of football heroes across Europe to support 'Back in Play', a European wide campaign to reach young ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: London (ots/PRNewswire) - - Not for UK Journalists - New Survey Reveals Widespread Ignorance of Debilitating Pain Condition Affecting Millions of Europeans Alarmingly, nearly sixty per cent of Europeans have never heard of neuropathic pain (NeP), ...http://www.presseportal.de/pm/14390/1280187/europeans-face-a-painful-truth-on-first-ever-neuropathic-pain-day-october-13/rssSun, 12 Oct 2008 01:07:02 +0200http://www.presseportal.de/pm/14390/1280187/europeans-face-a-painful-truth-on-first-ever-neuropathic-pain-day-october-13/rss Pfizer Inc. [Pressemappe]
London (ots/PRNewswire) - - Not for UK Journalists - New Survey Reveals Widespread Ignorance of Debilitating Pain Condition Affecting Millions of Europeans Alarmingly, nearly sixty per cent of Europeans have never heard of neuropathic pain (NeP), ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: Los Angeles (ots/PRNewswire) - - Entscheidende Ergebnisse auf der 14. Conference on Retroviruses and Opportunistic Infections (CROI)vorgestellt - Beschleunigte Prüfung von Maraviroc in den USA und Europa Auf der in dieser Woche ...http://www.presseportal.de/pm/14390/949226/maraviroc-das-neuartige-medikament-von-pfizer-gegen-hiv-senkt-signifikant-die-viruslast-bei-der/rssFri, 02 Mar 2007 12:37:26 +0100http://www.presseportal.de/pm/14390/949226/maraviroc-das-neuartige-medikament-von-pfizer-gegen-hiv-senkt-signifikant-die-viruslast-bei-der/rss Pfizer Inc. [Pressemappe]
Los Angeles (ots/PRNewswire) - - Entscheidende Ergebnisse auf der 14. Conference on Retroviruses and Opportunistic Infections (CROI)vorgestellt - Beschleunigte Prüfung von Maraviroc in den USA und Europa Auf der in dieser Woche ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale of a generic version of Lipitor by ...http://www.presseportal.de/pm/14390/945822/danish-court-issues-preliminary-injunction-that-prohibits-sale-of-generic-lipitor-product/rssFri, 23 Feb 2007 14:57:30 +0100http://www.presseportal.de/pm/14390/945822/danish-court-issues-preliminary-injunction-that-prohibits-sale-of-generic-lipitor-product/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale of a generic version of Lipitor by ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - - Celebrex to be Available in Europe for the Treatment of Ankylosing Spondylitis, a Debilitating Form of Arthritis Pfizer Inc announced today that 17 European countries agreed to extend the Celebrex (celecoxib ...http://www.presseportal.de/pm/14390/945502/celebrex-label-extended-for-new-use-in-europe/rssFri, 23 Feb 2007 10:05:27 +0100http://www.presseportal.de/pm/14390/945502/celebrex-label-extended-for-new-use-in-europe/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - - Celebrex to be Available in Europe for the Treatment of Ankylosing Spondylitis, a Debilitating Form of Arthritis Pfizer Inc announced today that 17 European countries agreed to extend the Celebrex (celecoxib ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - - If Approved, Maraviroc will be the First in a New Class of Medications Available for HIV Treatment Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated ...http://www.presseportal.de/pm/14390/940833/pfizer-s-maraviroc-to-receive-accelerated-regulatory-reviews-in-the-u-s-and-europe/rssTue, 13 Feb 2007 13:09:42 +0100http://www.presseportal.de/pm/14390/940833/pfizer-s-maraviroc-to-receive-accelerated-regulatory-reviews-in-the-u-s-and-europe/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - - If Approved, Maraviroc will be the First in a New Class of Medications Available for HIV Treatment Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - - Full marketing authorization and extension of indication to first-line treatment of advanced and/or metastatic renal cell carcinoma (MRCC) - First multiple receptor tyrosine kinase inhibitor to be approved in ...http://www.presseportal.de/pm/14390/928416/pfizer-s-sutent-r-is-granted-full-marketing-authorization-for-first-line-use-in-advanced-kidney/rssThu, 18 Jan 2007 10:08:37 +0100http://www.presseportal.de/pm/14390/928416/pfizer-s-sutent-r-is-granted-full-marketing-authorization-for-first-line-use-in-advanced-kidney/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - - Full marketing authorization and extension of indication to first-line treatment of advanced and/or metastatic renal cell carcinoma (MRCC) - First multiple receptor tyrosine kinase inhibitor to be approved in ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: Brüssel (ots/PRNewswire) - - Die Bevölkerungsstruktur ist alarmierend. Das Ausmass des Problems: Bis 2050 werden Schätzungen zufolge Menschen über 60 ein Drittel der europäischen Bevölkerung ausmachen [1] - die Gruppe der über 80jährigen soll ...http://www.presseportal.de/pm/14390/912113/das-gesundheitswesen-in-europa-nachhaltig-finanzieren-was-bekommen-wir-fuer-unser-geld/rssFri, 08 Dec 2006 00:27:32 +0100http://www.presseportal.de/pm/14390/912113/das-gesundheitswesen-in-europa-nachhaltig-finanzieren-was-bekommen-wir-fuer-unser-geld/rss Pfizer Inc. [Pressemappe]
Brüssel (ots/PRNewswire) - - Die Bevölkerungsstruktur ist alarmierend. Das Ausmass des Problems: Bis 2050 werden Schätzungen zufolge Menschen über 60 ein Drittel der europäischen Bevölkerung ausmachen [1] - die Gruppe der über 80jährigen soll ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - - Broad Access Program for Patients with Limited Available Treatment Options Pfizer announced today that it plans to establish a multi-national Expanded Access Program (EAP) to make the investigational ...http://www.presseportal.de/pm/14390/908878/pfizer-announces-plans-to-establish-expanded-access-program-for-maraviroc-investigational-hiv-ccr5/rssFri, 01 Dec 2006 06:04:02 +0100http://www.presseportal.de/pm/14390/908878/pfizer-announces-plans-to-establish-expanded-access-program-for-maraviroc-investigational-hiv-ccr5/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - - Broad Access Program for Patients with Limited Available Treatment Options Pfizer announced today that it plans to establish a multi-national Expanded Access Program (EAP) to make the investigational ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: Las Vegas, November 15 (ots/PRNewswire) - - New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma - Analysis finds that ...http://www.presseportal.de/pm/14390/901628/results-of-new-combined-analysis-concludes-patients-at-risk-for-glaucoma-will-benefit-from-risk/rssWed, 15 Nov 2006 19:00:52 +0100http://www.presseportal.de/pm/14390/901628/results-of-new-combined-analysis-concludes-patients-at-risk-for-glaucoma-will-benefit-from-risk/rss Pfizer Inc. [Pressemappe]
Las Vegas, November 15 (ots/PRNewswire) - - New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma - Analysis finds that ... Lesen Sie hier weiter...
]]>Finanzenredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - - Madrid, Spain Court of Appeal Confirms Pfizer's Patent Claims Pfizer Inc said today that the European Patent Office (EPO) has issued an opinion upholding, in its entirety, the company's calcium salt patent ...http://www.presseportal.de/pm/14390/892947/european-patent-office-supports-validity-of-lipitor-patent/rssFri, 27 Oct 2006 19:32:00 +0200http://www.presseportal.de/pm/14390/892947/european-patent-office-supports-validity-of-lipitor-patent/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - - Madrid, Spain Court of Appeal Confirms Pfizer's Patent Claims Pfizer Inc said today that the European Patent Office (EPO) has issued an opinion upholding, in its entirety, the company's calcium salt patent ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - - Company Opens its Compound Library to Help Search for New Anti-Parasitic Medicines Pfizer announced today collaboration that gives access to its library of medicinal compounds -- the world's largest -- and ...http://www.presseportal.de/pm/14390/891970/pfizer-assists-world-health-organization-in-search-for-new-treatments-against-diseases-of-the/rssThu, 26 Oct 2006 11:03:32 +0200http://www.presseportal.de/pm/14390/891970/pfizer-assists-world-health-organization-in-search-for-new-treatments-against-diseases-of-the/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - - Company Opens its Compound Library to Help Search for New Anti-Parasitic Medicines Pfizer announced today collaboration that gives access to its library of medicinal compounds -- the world's largest -- and ... Lesen Sie hier weiter...
]]>Finanzenredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer ...http://www.presseportal.de/pm/14390/887619/austrian-patent-office-rules-in-pfizer-s-favor-ranbaxy-product-would-infringe-basic-lipitor-patent/rssTue, 17 Oct 2006 12:47:15 +0200http://www.presseportal.de/pm/14390/887619/austrian-patent-office-rules-in-pfizer-s-favor-ranbaxy-product-would-infringe-basic-lipitor-patent/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPfizer Inc.: New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A ...http://www.presseportal.de/pm/14390/875043/pfizer-s-lyrica-r-approved-in-europe-for-difficult-to-treat-nerve-pain/rssMon, 18 Sep 2006 21:04:37 +0200http://www.presseportal.de/pm/14390/875043/pfizer-s-lyrica-r-approved-in-europe-for-difficult-to-treat-nerve-pain/rss Pfizer Inc. [Pressemappe]
New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas Technologies